British pharmaceutical giant AstraZeneca announced on Tuesday, July 29, 2025, that its net profit jumped by 27 percent in the second quarter of the year, significantly boosted by record growth in its crucial US market.
The company reported a profit after tax of $2.45 billion for the three months ending June. This strong performance follows AstraZeneca’s recently announced multi-billion-dollar investment strategy in the United States, designed to expand its manufacturing and research capabilities.
Pascal Soriot, Chief Executive Officer of AstraZeneca, highlighted the company’s robust momentum. “Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent,” Soriot stated in the earnings announcement. He also reaffirmed the company’s commitment to further growth in the US, citing a pledged $50 billion investment, which includes the largest manufacturing investment in AstraZeneca’s history, set for Virginia. This landmark investment, totaling $50 billion by 2030, aims to strengthen America’s leadership in medicine manufacturing and R&D.
The United States has emerged as a critical market for AstraZeneca, accounting for 44 percent of the company’s total revenue in the second quarter, with US revenue alone jumping by a record 13 percent. AstraZeneca expects the US to contribute 50% of its total revenue by 2030, underpinning its ambitious target of reaching $80 billion in revenue by the same year.
This substantial investment and strong financial performance come amidst a broader trend of pharmaceutical companies increasing their presence in the US, partly influenced by the Trump administration’s threats of tariffs on imported drugs.
